Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Several other equities research analysts have also recently commented on DRNA. HC Wainwright started coverage on shares of Dicerna Pharmaceuticals in a research report on Monday, December 12th. They issued a “buy” rating and a $7.00 target price for the company. Leerink Swann started coverage on shares of Dicerna Pharmaceuticals in a research report on Tuesday, January 31st. They set a “market perform” rating and a $4.00 price target for the company. Finally, Jefferies Group LLC reissued a “buy” rating and set a $7.00 price target (down from $8.00) on shares of Dicerna Pharmaceuticals in a research report on Sunday, April 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $5.88.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 1.61% on Tuesday, hitting $3.05. The stock had a trading volume of 199,286 shares. The firm’s market capitalization is $63.42 million. Dicerna Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $6.10. The company has a 50 day moving average of $2.99 and a 200-day moving average of $3.19.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, March 30th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.05. The firm earned $0.13 million during the quarter. Equities analysts predict that Dicerna Pharmaceuticals will post ($2.57) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Dicerna Pharmaceuticals Inc (DRNA) Downgraded by Zacks Investment Research to Sell” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/20/dicerna-pharmaceuticals-inc-drna-rating-lowered-to-sell-at-zacks-investment-research-updated.html.
A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in shares of Dicerna Pharmaceuticals by 7.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,978 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 2,705 shares during the period. Renaissance Technologies LLC increased its position in shares of Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 84,682 shares in the last quarter. Finally, RTW Investments LP increased its position in shares of Dicerna Pharmaceuticals by 0.8% in the fourth quarter. RTW Investments LP now owns 2,043,216 shares of the biopharmaceutical company’s stock valued at $5,884,000 after buying an additional 16,322 shares in the last quarter. Institutional investors own 58.56% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.